financetom
Business
financetom
/
Business
/
BASF sues Berkshire's Duracell for allegedly stealing battery secrets
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BASF sues Berkshire's Duracell for allegedly stealing battery secrets
Apr 9, 2025 9:59 AM

April 9 (Reuters) - Duracell, the battery maker owned by

Warren Buffett's Berkshire Hathaway ( BRK/A ), has been sued by

BASF for allegedly stealing trade secrets related to

the German chemical company's lithium ion battery technology,

court documents showed.

In a heavily redacted complaint made public on Tuesday in

Delaware federal court, BASF said the trade secrets related to

its efforts over several years to manufacture lower-cost

materials for high-powered batteries.

Duracell did not immediately respond to requests for comment

on Wednesday.

In the complaint, BASF said it invested substantial

resources in creating a proprietary and trade-secret process for

producing high-performance cathode material, a battery component

it called "crucial".

But it said Duracell misappropriated secrets while the

companies had a collaboration agreement, shared details with a

third party, and arranged for manufacturing under the false

pretense that BASF's process came from Duracell.

By "cutting BASF out of its role as developer and supplier,"

Duracell caused "substantial and irreparable injury," justifying

damages, BASF said.

Lithium ion batteries are used in many products including

consumer electronics, electric vehicles, appliances, toys and

energy storage systems.

BASF announced a plan in December 2023 to separate its

battery chemicals business and two other businesses into

autonomous units, to help boost earnings.

Berkshire bought Duracell from Procter & Gamble ( PG ) for

about $2.9 billion in 2016.

The case is BASF Corp. v. Duracell U.S. Operations Inc, U.S.

District Court, District of Delaware, No. 25-00404.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease
Mar 27, 2025
01:33 PM EDT, 03/27/2025 (MT Newswires) -- Regulus Therapeutics ( RGLS ) said Thursday it has completed its phase 1b clinical trial of farabursen for the treatment of autosomal dominant polycystic kidney disease, with full data from the fourth cohort confirming the 300mg fixed dose selection to achieve optimal kidney exposure. The company said that over four months, patients treated...
TikTok Shop steps up Europe expansion with US future unclear
TikTok Shop steps up Europe expansion with US future unclear
Mar 27, 2025
LONDON (Reuters) - E-commerce platform TikTok Shop said it will launch to users in France, Germany, and Italy on Monday, expanding its reach further into Europe even as TikTok faces being shut down in the U.S. if Chinese owner ByteDance does not find an American buyer. The shopping arm of social media app TikTok has been available in the UK...
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Mar 27, 2025
LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edge over U.S. rival Eli Lilly. The Danish drugmaker's launch of weight-loss injection Wegovy propelled it to become Europe's most valuable company by...
Petco's Strong Core Profit Guidance Reflects Progress on Turnaround, Wedbush Says; Stock Soars
Petco's Strong Core Profit Guidance Reflects Progress on Turnaround, Wedbush Says; Stock Soars
Mar 27, 2025
01:30 PM EDT, 03/27/2025 (MT Newswires) -- Petco Health & Wellness' (WOOF) better-than-expected core profit results and guidance signal solid progress on its turnaround efforts, Wedbush Securities said Thursday. The pet store chain late Wednesday reported fiscal fourth-quarter adjusted earnings before interest, taxes, depreciation and amortization of $96.1 million, topping Wall Street's view for $91.5 million. The company expects adjusted...
Copyright 2023-2026 - www.financetom.com All Rights Reserved